Amundi
VERV

Amundi’s Verve Therapeutics VERV Stock Holding History

Amundi’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,398
Closed -$13.1K – 2162
2025
Q1 		$13.1K Sell
3,398
-9
-0.3% -$60 ﹤0.01% 1873
2024
Q4 		$20.5K Buy
3,407
+199
+6% +$1.12K ﹤0.01% 1888
2024
Q3 		$14.5K Hold
3,208
– – ﹤0.01% 1918
2024
Q2 		$16.5K Buy
+3,208
New +$20.2K ﹤0.01% 1859
2023
Q2 		– Sell
-200
Closed -$2.67K – 2134
2023
Q1 		$2.67K Sell
200
-1,894
-90% -$37.1K ﹤0.01% 2036
2022
Q4 		$45.5K Buy
+2,094
New +$55.5K ﹤0.01% 1713

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Amundi's VERV Position: Q2 2025 in Review

Amundi sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 3,398 shares — an estimated $13.1K sold.

Amundi first reported a position in VERV in Q4 2022 and held it in 6 quarters. The position peaked at $45.5K in Q4 2022. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Amundi reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 3,398 Verve Therapeutics shares in Q2 2025, an estimated $13.1K.
  • Amundi first reported a position in Verve Therapeutics in Q4 2022 and held it in 6 quarters.
  • Amundi's Verve Therapeutics position peaked at $45.5K in Q4 2022.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.